What did PainChek (ASX:PCK) announce regarding its capital raising?

PainChek (ASX:PCK) entered into binding agreements to raise A$5.5 million through the issuance of unsecured convertible notes. The single-tranche funding round was exclusively supported by a small group of the company's existing professional and sophisticated investor-shareholders.

Why does PainChek (ASX:PCK) need this A$5.5 million capital injection?

The digital health firm is using the funds to bolster its general working capital and accelerate its commercial sales expansion across North America. This runway is critical following its landmark Sabra agreement covering 350 US aged-care facilities and its newly secured access to US remote therapeutic monitoring reimbursement pathways.

What are the key terms of the PainChek (ASX:PCK) convertible notes?

The unsecured notes have a 12-month maturity period, a face value of A$50,000, and required a minimum subscription of A$100,000 per investor. Noteholders receive monthly interest payments in cash and can convert their debt into equity at a fixed conversion price of A$0.195 per share at any time before maturity.

What is the conversion premium compared to the PainChek (ASX:PCK) current share price?

The convertible notes feature a fixed conversion price of A$0.195 per share, which is a significant premium to PainChek’s share price of A$0.14 at the time of reporting. If the stock stays below A$0.195, noteholders are less likely to convert, meaning the company would have to repay the principal in cash at maturity.

What sweetener options are being offered to PainChek (ASX:PCK) noteholders?

Subject to shareholder approval and successful equity conversion, noteholders will receive one free attaching option for every two shares issued upon conversion. This structure offers existing sophisticated investors a strong upside incentive if the company executes its growth strategy successfully.

What does this capital raising mean for existing retail shareholders of PainChek (ASX:PCK)?

Because the conversion price ($0.195) is well above the trading price (A$0.14), there is no immediate dilution for everyday retail investors. However, if the share price rises and noteholders convert their debt plus options into equity, existing shareholders will face future EPS and ownership dilution.

Image for illustrative purposes only. Not a real photo.

PainChek raises $5.5M for US market expansion

Written by Liezl GambePublished May 22, 2026, 3:46 AM

PainChek (ASX:PCK) entered into binding agreements to raise $5.5 million through the issuance of unsecured convertible notes.

The financing initiative is tailored to bolster the company’s general working capital and support its ongoing sales expansion across North America.

The capital injection arrives at a critical juncture for the digital health firm, following its landmark Sabra agreement which spans 350 US aged-care facilities, alongside newly secured access to remote therapeutic monitoring reimbursement pathways.

The funding round was exclusively supported by a small, select group of PainChek’s existing professional and sophisticated investor-shareholders.

Issued in a single tranche, the convertible notes carry a 12-month maturity period with a face value of $50,000 per note, requiring a minimum subscription of $100,000 per investor.

Noteholders maintain the flexibility to convert their notes into company shares at any time prior to maturity at a fixed conversion price of $0.195, with interest payments distributed monthly in cash.

Furthermore, subject to shareholder approval and successful equity conversion, investors will receive one free attaching option for every two shares issued.

PainChek CEO Philip Daffas expressed strong confidence in the capital raise, noting that the funds provide the essential financial runway to accelerate the company’s North American growth initiatives and broader commercial expansion strategy.

At the time of reporting, PainChek’s share price was $0.14.